SCHEMBL2817549

SCHEMBL2817549

CN(C)C(=O)C1(c2cc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c3cnn(C)c3n2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 6/20 0.48
CSF1R P07333 5/20 0.48
FLT1 P17948 5/20 0.48
LCK P06239 5/20 0.48
FYN P06241 5/20 0.48
NTRK1 P04629 5/20 0.48
AURKB Q96GD4 5/20 0.48
KIT P10721 4/20 0.48
FLT4 P35916 4/20 0.48
LYN P07948 4/20 0.48
SRC P12931 4/20 0.48
NTRK2 Q16620 4/20 0.48
EPHA2 P29317 4/20 0.48
MAP4K2 Q12851 4/20 0.48
TAOK1 Q7L7X3 4/20 0.48
MAP3K20 Q9NYL2 4/20 0.48
ABL1 P00519 4/20 0.48
NEK2 P51955 4/20 0.48
BLK P51451 3/20 0.48
JAK2 O60674 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4073928 0.92 KDR (0.48) FLT3CSF1RFLT1LCKFYN
SCHEMBL12973413 0.91 LMNA (0.46) FLT3CSF1RFLT1LCKFYN
SCHEMBL12973426 0.91 KDR (0.51) FLT3CSF1RFLT1LCKFYN
SCHEMBL12973415 0.89 KDR (0.57) FLT3CSF1RFLT1LCKFYN
SCHEMBL2817544 0.88 CSF1R (0.47) FLT3CSF1RFLT1LCKFYN
SCHEMBL2816690 0.87 CSF1R (0.48) FLT3CSF1RFLT1LCKFYN
SCHEMBL12973411 0.87 IDH2 (0.49) FLT3CSF1RFLT1LCKFYN
SCHEMBL12973414 0.87 KDR (0.45) FLT3KITAURKAALKKDR
SCHEMBL2816642 0.85 KDR (0.64) FLT3CSF1RFLT1LCKFYN
SCHEMBL12973417 0.84 KDR (0.51) FLT3CSF1RFLT1LCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846928-B2 Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-12-07 US claimed
US-20080058326-A1 SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-03-06 US claimed
EP-2061790-B1 Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them BAYER IP GMBH (DE) 2014-08-13 EP disclosed
US-7846928-B2 Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-12-07 US disclosed
US-7846928-B2 Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-12-07 US disclosed
US-7846928-B2 Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-12-07 US disclosed
US-20080058326-A1 SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-03-06 US disclosed
US-20080058326-A1 SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-03-06 US disclosed
US-20080058326-A1 SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058326-A1 SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME KDR, TIE1, FLT1 FLT3 39/4885CSF1R 944/4885FLT1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.